NCT04199026View on ClinicalTrials.gov

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic SarcomaRecurrent SarcomaResectable Sarcoma
Interventions
DRUG

Doxorubicin

Given via microdevice

DRUG

Doxorubicin Hydrochloride

Given via microdevice

DEVICE

Drug Delivery Microdevice

Undergo percutaneous implantation of drug delivery microdevice

DRUG

Everolimus

Given via microdevice

BIOLOGICAL

Ganitumab

Given via microdevice

DRUG

Ifosfamide

Given via microdevice

DRUG

Irinotecan

Given via microdevice

DRUG

Pazopanib

Given via microdevice

DRUG

Polyethylene Glycol

Given via microdevice

DRUG

Temozolomide

Given via microdevice

DRUG

Temsirolimus

Given via microdevice

PROCEDURE

Therapeutic Conventional Surgery

Undergo standard of care surgery

DRUG

Vincristine

Given via microdevice

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER